Qiagen NV (NYSE:QGEN) Position Lessened by Legal & General Group Plc

Legal & General Group Plc lessened its holdings in shares of Qiagen NV (NYSE:QGEN) by 17.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,572,596 shares of the company’s stock after selling 335,694 shares during the period. Legal & General Group Plc owned 0.69% of Qiagen worth $47,500,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Lindbrook Capital LLC bought a new position in shares of Qiagen during the 4th quarter worth approximately $25,000. Captrust Financial Advisors lifted its holdings in Qiagen by 165.3% during the 4th quarter. Captrust Financial Advisors now owns 1,008 shares of the company’s stock worth $35,000 after purchasing an additional 628 shares during the last quarter. Bremer Trust National Association acquired a new stake in Qiagen during the 4th quarter worth approximately $45,000. Fort L.P. acquired a new position in Qiagen in the 4th quarter valued at $68,000. Finally, Oppenheimer Asset Management Inc. acquired a new position in Qiagen in the 4th quarter valued at $118,000. 64.77% of the stock is currently owned by institutional investors.

A number of research firms have recently commented on QGEN. Zacks Investment Research cut Qiagen from a “hold” rating to a “sell” rating in a report on Tuesday, April 9th. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a report on Friday, April 12th. UBS Group assumed coverage on Qiagen in a research report on Friday, March 15th. They set a “neutral” rating and a $42.00 price objective on the stock. Finally, Jefferies Financial Group restated a “neutral” rating on shares of Qiagen in a research report on Monday, January 21st. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Qiagen presently has a consensus rating of “Buy” and a consensus price target of $41.71.

QGEN stock traded down $0.23 during trading on Friday, reaching $38.30. 1,853,908 shares of the stock were exchanged, compared to its average volume of 1,011,793. Qiagen NV has a twelve month low of $31.93 and a twelve month high of $41.55. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.05 and a current ratio of 2.22. The company has a market cap of $8.64 billion, a P/E ratio of 28.58, a price-to-earnings-growth ratio of 2.14 and a beta of 0.92.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Monday, February 4th. The company reported $0.40 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.40. The business had revenue of $403.20 million for the quarter, compared to the consensus estimate of $409.32 million. Qiagen had a return on equity of 12.15% and a net margin of 12.68%. The firm’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.43 EPS. Equities analysts predict that Qiagen NV will post 1.46 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/04/21/legal-general-group-plc-has-47-50-million-stake-in-qiagen-nv-qgen.html.

Qiagen Profile

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

Further Reading: The Role of a Fiduciary and Individual Investors

Institutional Ownership by Quarter for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.